医学部 内科学(ばんたね病院)

fujiwara wakaya

  (藤原 稚也)

Profile Information

Affiliation
Fujita Health University

J-GLOBAL ID
201501000027701627
researchmap Member ID
7000012725

Research Areas

 1

Papers

 23
  • Wakaya Fujiwara, Hideki Ishii, Yoshihiro Sobue, Shinya Shimizu, Tomoya Ishiguro, Ryo Yamada, Sayano Ueda, Hideto Nishimura, Yudai Niwa, Akane Miyazaki, Wataru Miyagi, Shuhei Takahara, Hiroyuki Naruse, Junichi Ishii, Ken Kiyono, Eiichi Watanabe, Hideo Izawa
    Scientific Reports, 12(1), Dec, 2022  
    Contrast-associated acute kidney injury (CA-AKI) is a complication of percutaneous coronary intervention (PCI). Because proteinuria is a sentinel marker of renal dysfunction, we assessed its role in predicting CA-AKI in patients undergoing PCI. A total of 1,254 patients undergoing PCI were randomly assigned to a derivation (n = 840) and validation (n = 414) dataset. We identified the independent predictors of CA-AKI where CA-AKI was defined by the new criteria issued in 2020, by a multivariate logistic regression in the derivation dataset. We created a risk score from the remaining predictors. The discrimination and calibration of the risk score in the validation dataset were assessed by the area under the receiver-operating characteristic curves (AUC) and Hosmer–Lemeshow test, respectively. A total of 64 (5.1%) patients developed CA-AKI. The 3 variables of the risk score were emergency procedures, serum creatinine, and proteinuria, which were assigned 1 point each based on the correlation coefficient. The risk score demonstrated a good discriminative power (AUC 0.789, 95% CI 0.766–0.912) and significant calibration. It was strongly associated with the onset of CA-AKI (Cochran-Armitage test, p < 0.0001). Our risk score that included proteinuria was simple to obtain and calculate, and may be useful in assessing the CA-AKI risk before PCI.
  • Hiroyuki Naruse, Junnichi Ishii, Hiroshi Takahashi, Fumihiko Kitagawa, Eirin Sakaguchi, Hideto Nishimura, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Akira Yamada, Wakaya Fujiwara, Mutsuharu Hayashi, Sadako Motoyama, Masayoshi Sarai, Eiichi Watanabe, Hiroyasu Ito, Yukio Ozaki, Hideo Izawa
    Journal of clinical medicine, 10(16), Aug 13, 2021  
    The prognostic role of D-dimer in different types of heart failure (HF) is poorly understood. We investigated the prognostic value of D-dimer on admission, both independently and in combination with the Get With The Guidelines-Heart Failure (GWTG-HF) risk score and N-terminal pro-B-type natriuretic peptide (NT-proBNP), in patients with preserved left ventricular ejection fraction (LVEF) and acute decompensated HF (HFpEF) or reduced LVEF (HFrEF). Baseline D-dimer levels were measured on admission in 1670 patients (mean age: 75 years) who were hospitalized for worsening HF. Of those patients, 586 (35%) were categorized as HFpEF (LVEF ≥ 50%) and 1084 as HFrEF (LVEF < 50%). During the 12-month follow-up period after admission, 360 patients died. Elevated levels (at least the highest tertile value) of D-dimer, GWTG-HF risk score, and NT-proBNP were all independently associated with mortality in all HFpEF and HFrEF patients (all p < 0.05). Adding D-dimer to a baseline model with a GWTG-HF risk score and NT-proBNP improved the net reclassification and integrated discrimination improvement for mortality greater than the baseline model alone in all populations (all p < 0.001). The number of elevations in D-dimer, GWTG-HF risk score, and NT-proBNP were independently associated with a higher risk of mortality in all study populations (HFpEF and HFrEF patients; all p < 0.001). The combination of D-dimer, which is independently predictive of mortality, with the GWTG-HF risk score and NT-proBNP could improve early prediction of 12-month mortality in patients with acute decompensated HF, regardless of the HF phenotype.
  • Yuji Kono, Hideo Izawa, Yoichiro Aoyagi, Ryo Yamada, Tomoya Ishiguro, Masataka Yoshinaga, Satoshi Okumura, Wakaya Fujiwara, Mutsuharu Hayashi, Yohei Otaka
    Heart and vessels, 36(12) 1856-1860, Jun 3, 2021  
    The study aimed to identify factors related to bone mineral density (BMD) among older patients with heart failure (HF). A total of 70 consecutive patients with HF aged 65 years or older who were admitted to an acute hospital due to worsening condition were enrolled before discharge. BMD of the femoral neck was evaluated using the DEXA method. Physical function, as well as echocardiographic and laboratory findings including biomarker of HF severity were collected. Bivariate and multiple regression analyses were employed to determine the association between BMD and the clinical variables. Bivariate analysis determined that age, grip strength, walking speed, serum albumin, and N-terminal pro B-type natriuretic peptide (NT-proBNP) were significantly correlated with BMD (P < 0.01), whereas other clinical parameters were not. The multiple regression analysis identified NT-proBNP as an independent related factor for BMD after adjusting with confounding clinical variables. NT-proBNP was independently related to BMD among older patients with HF. Our results suggest the inclusion of bone fracture prevention strategies in disease management programs, especially for older patients with HF.
  • Ueda Sayano, Kono Yuji, Yamada Ryo, Ishiguro Tomoya, Yoshinaga Masataka, Okumura Satoshi, Fujiwara Wakaya, Hayashi Mutsuharu, Aoyagi Yoichiro, Saitoh Eiichi, Otaka Yohei, Izawa Hideo
    Fujita Medical Journal, 7(2) 65-69, May, 2021  
  • Tomoya Ishiguro, Mutsuharu Hayashi, Wakaya Fujiwara, Satoshi Okumura, Masataka Yoshinaga, Ryo Yamada, Sayano Ueda, Takehiro Ito, Yudai Niwa, Akane Miyazaki, Masahide Harada, Hiroyuki Naruse, Junnichi Ishii, Yukio Ozaki, Hideo Izawa
    Fujita medical journal, 7(1) 18-22, 2021  
    OBJECTIVES: MicroRNAs (miRNA) are functional RNAs that have emerged as pivotal gene expression regulators in cardiac disease. Although several cardiomyocyte miRNAs have been reported to play roles in heart failure progression among patients with idiopathic dilated cardiomyopathy (DCM), the role of circulating miRNAs has not yet been well-examined. METHODS: After total RNA extraction from the peripheral blood samples of three control participants and six patients with DCM, miRNA profiling was performed using miRNA arrays. Based on the results of this initial screening, real-time polymerase chain reaction (RT-PCR) was used to perform a quantitative analysis of blood samples from a larger number of matched patients (DCM, n=20; controls, n=5). Finally, the correlations between specific miRNA expression levels and hemodynamic parameters were analyzed. RESULTS: A primary screening of 2,565 miRNAs resulted in the identification of nine miRNA candidates. Quantitative RT-PCR results revealed significantly increased miR-489 expression levels in the DCM group. Moreover, there was a significant positive correlation between miR-489 expression level and left ventricular ejection fraction. CONCLUSIONS: Our results suggest that circulating miR-489 could be a potential noninvasive diagnostic biomarker for DCM. Additionally, the quantification of circulating miR-489 may have value as a potential prognostic marker for patients with DCM.

Misc.

 36
  • 河野 裕治, 井澤 英夫, 青柳 陽一郎, 山田 亮, 石黒 智也, 良永 真隆, 奥村 聡, 藤原 稚也, 林 睦晴, 才藤 栄一
    日本循環器学会学術集会抄録集, 83回 CP03-1, Mar, 2019  
  • 河野裕治, 井澤英夫, 青柳陽一郎, 山田亮, 石黒智也, 良永真隆, 奥村聡, 藤原稚也, 林睦晴, 才藤栄一
    日本心不全学会学術集会プログラム・抄録集, 23rd, 2019  
  • Wakaya Fujiwara, Yasuchika Kato, Mutsuharu Hayashi, Yoshinori Sugishita, Satoshi Okumura, Masataka Yoshinaga, Tomoya Ishiguro, Ryo Yamada, Sayano Ueda, Masahide Harada, Hiroyuki Naruse, Junnichi Ishii, Yukio Ozaki, Hideo Izawa
    Journal of cardiology, 72(6) 452-457, Dec, 2018  Peer-reviewed
    BACKGROUND: Although cardiac sarcoidosis is associated with poor prognosis, diagnosis of the disease is challenging and the sensitivity and specificity of diagnostic modalities are limited. This study was performed to evaluate the potential of serum microRNAs (miRNAs) as diagnostic biomarkers for cardiac sarcoidosis. METHODS: We performed genome-wide expression profiling for 2565 miRNAs (Human-miRNA ver.21) using peripheral blood samples from 5 patients with cardiac sarcoidosis (61±9 years) and 3 healthy controls (54±7 years). From this screening study, we selected 12 miRNAs that were significantly related to cardiac sarcoidosis. Next, we performed real-time polymerase chain reaction (PCR) on blood samples from 15 new patients with cardiac sarcoidosis and 4 healthy controls to quantify the expression of these 12 miRNAs. RESULTS: In the screening study, 12 miRNAs were differentially expressed (p<0.01) in all 5 patients with cardiac sarcoidosis, showing greater fold-change values (>4 or <0.25) compared with the expression in the 3 healthy controls. Analysis of the real-time PCR for blood samples from the other 15 patients and 4 controls using Mann-Whitney U tests revealed that the expression of miR-126 and miR-223 was significantly higher in the patients than in the healthy individuals. However, there were no differences in the expressions of miRNA-126 and miR-223 between patients with only cardiac lesions and those with extra-cardiac lesions. CONCLUSIONS: Our results demonstrate the potential of serum miR-126 and miR-223 as new-generation biomarkers for the differential diagnosis of cardiac sarcoidosis in patients with heart failure.
  • 森 悦子, 河野 裕治, 石川 綾子, 杉浦 翼, 田中 康友, 青柳 陽一郎, 上田 清乃, 山田 亮, 石黒 智也, 藤原 稚也, 林 睦晴, 井澤 英夫
    心臓リハビリテーション, 24(3-4) 232-235, Nov, 2018  
    【目的】本研究の目的は、高齢心不全患者を対象に抑うつと身体機能との関連を検討した。【方法】65歳以上の心不全患者120例を対象とした。対象者をGeriatric Depression Scale(GDS-5)で抑うつなし群(GDS-5≦1)、抑うつあり群(GDS-5≧2)の2群に分け、心不全病態指標、身体機能、認知機能の項目についてχ2検定、対応のないt-検定を用いて比較した。【結果】全対象者のうち抑うつは58例(48%)に認めた。両群間の比較では年齢、性別、BMI、認知機能、病態指標には差を認めなかった。しかし身体機能(握力、等尺性膝伸展筋力、6分間歩行距離、歩行速度)は、抑うつ群で有意に低値を示した。【結論】本結果より高齢心不全患者の抑うつ合併例は身体機能が低下していることが明らかとなった。高齢心不全患者に対する身体的フレイル判定の際には、抑うつも評価する必要性が示唆された。(著者抄録)
  • 井澤英夫, 河野裕治, 青柳陽一郎, 上田清乃, 山田亮, 石黒智也, 良永真隆, 奥村聡, 藤原稚也, 林睦晴
    日本心不全学会学術集会プログラム・抄録集, 22nd, 2018  

Books and Other Publications

 1

Presentations

 19

Research Projects

 3